Research Progress of Lymph Node Dissection in Treatment of cN0 Papillary Thyroid Microcarcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 CUIPeng ¹ , XUDe-quan ² , YINYue ² ,  DAIWen-jie ²

1. Department of General Surgery, Pudong Hospital of Shanghai, Shanghai 200210, China;
2. Department of Thyroid and Breast Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China;

Corresponding author：

DAIWen-jie, Email: davidhmu@163.com

Keywords：

Papillary thyroid microcarcinoma; Central lymph node metastasis; Prophylactic central lymph node dissection

DOI：

10.7507/1007-9424.20150368

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To analyze the predictive factors for central lymph node metastasis in papillary thyroid microcarcinoma (PTMC), and explore the treatment method for the patients with PTMC. Method The literatures were reviewed according to the results searched from PubMed in recent years. Results Central lymph node metastases were common in the patients with PTMC. It was important for prophylactic central lymph node dissection so it might reduce the local recurrence and comfirm the clinical staging, further more provide the strategies for the postoperative therapy. Conclusions Lymphadenectomy is necessary for patients with lymph node metastasis. Prophylactic central lymph node dissection should be performed for patients without lymph node metastasis but with one risk factor or more.

Citation： CUIPeng, XUDe-quan, YINYue, DAIWen-jie. Research Progress of Lymph Node Dissection in Treatment of cN0 Papillary Thyroid Microcarcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(11): 1405-1409. doi: 10.7507/1007-9424.20150368 Copy

1.	徐德全, 代文杰.甲状腺髓样癌的靶向治疗.中国普外基础与临床杂志, 2014, 21(12):1579-1582.
2.	World Cancer Report. Version 2014. http://www.iarc.fr/en/publications/books/wcr/wcr-order.php.
3.	陈万青, 张思维, 曾红梅, 等.中国2010年恶性肿瘤发病与死亡.中国肿瘤, 2014, 23(1):1-10.
4.	Soares P, Celestino R, Gaspar Da Rocha A, et al. Papillary thyroid microcarcinoma:how to diagnose and manage this epidemic? Int J Surg Pathol, 2014, 22(2):113-119.
5.	Cupisti K, Lehwald N, Anlauf M, et al. Encapsulation status of papillary thyroid microcarcinomas is associated with the risk of lymph node metastases and tumor multifocality. Horm Metab Res, 2014, 46(2):138-144.
6.	Choi SJ, Kim TY, Lee JC, et al. Is routine central neck dissection necessary for the treatment of papillary thyroid microcarcinoma? Clin Exp Otorhinolaryngol, 2008, 1(1):41-45.
7.	Yu XM, Wan Y, Sippel RS, et al. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18445 cases. Ann Surg, 2011, 254(4):653-660.
8.	李建新, 杨雨民, 齐欣, 等.甲状腺微小癌的诊断和治疗.中国普外基础与临床杂志, 2012, 19(7):796-798.
9.	Kim BY, Jung CH, Kim JW, et al. Impact of clinicopathologic factors on subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Yonsei Med J, 2012, 53(5):924-930.
10.	Rosai J, Livolsi VA, Sobrinho-Simoes M, et al. Renaming papillary microcarcinoma of the thyroid gland:the Porto proposal. Int J Surg Pathol, 2003, 11(4):249-251.
11.	Lang BH, Lo CY, Chan WF, et al. Prognostic factors in papillary and follicular thyroid carcinoma:their implications for cancer staging. Ann Surg Oncol, 2007, 14(2):730-738.
12.	王深明, 叶润仪.甲状腺微小癌诊断与外科治疗规范化.中华普外科手术学杂志:电子版, 2013, 7(4):246-249.
13.	Zaydfudim V, Feurer ID, Griffin MR, et al. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery, 2008, 144(6):1070-1078.
14.	Wang Q, Chu B, Zhu J, et al. Clinical analysis of prophylactic central neck dissection for papillary thyroid carcinoma. Clin Transl Oncol, 2014, 16(1):44-48.
15.	Costa S, Giugliano G, Santoro L, et al. Role of prophylactic central neck dissection in cN0 papillary thyroid cancer. Acta Otorhinolaryngol Ital, 2009, 29(2):61-69.
16.	White ML, Gauger PG, Doherty GM. Central lymph node dissection in differentiated thyroid cancer. World J Surg, 2007, 31(5):895-904.
17.	NCCN Guidelines:Thyroid Carcinoma. Version 2, 2013.
18.	代文杰, 徐德全, 殷越.甲状腺结节手术范围合理选择——美国及我国相关指南解读.中国实用外科杂志, 2015, 35(6):604-607.
19.	Yoshida A. Guidelines for the management of thyroid tumors. Nihon Geka Gakkai Zasshi, 2012, 113(6):507-511.
20.	鄢丹桂, 张彬.甲状腺乳头状癌临床N0患者颈部淋巴结处理.中华耳鼻喉头颈外科杂志, 2012, 47(3):257-260.
21.	Pai SI, Tufano RP. Central compartment neck dissection for thyroid cancer. ORL J Otorhinolaryngol Relat Spec, 2008, 70(5):292-297.
22.	徐德全, 代文杰.分化型甲状腺癌术后促甲状腺激素抑制性治疗进展.中国实用外科杂志, 2013, 33(12):1071-1074.
23.	Dănilă R, Andriescu L, Grigorovici A, et al. Differentiated thyroid cancer-staging and prognostic systems. Rev Med Chir Soc Med Nat Iasi, 2005, 109(1):71-76.
24.	Shaha AR, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of thyroid. Surgery, 1994, 116(6):1036-1041.
25.	孙荣昊, 李超, 樊晋川.分化型甲状腺癌外科治疗要点问题分析-美国同行见解.中国实用外科杂志, 2014, 34(4):300-302.
26.	Niemeier LA, Kuffner Akatsu H, Song C, et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer, 2012, 118(8):2069-2077.
27.	Xu D, Lv X, Wang S, et al. Risk factors for predicting central lymph node metastasis in papillary thyroid microcarcinoma. Int J Clin Exp Pathol, 2014, 7(9):6199-6205.
28.	Cho SY, Lee TH, Ku YH, et al. Central lymph node metastasis in papillary thyroid microcarcinoma can be stratified according to the number, the size of metastatic foci, and the presence of desmoplasia. Surgery, 2015, 157(1):111-118.
29.	Hong YR, Yan CX, Mo GQ, et al. Conventional US, elastography, and contrast enhanced US features of papillary thyroid microcarcinoma predict central compartment lymph node metastases. Sci Rep, 2015, 5:7748.
30.	So YK, Son YI, Hong SD, et al. Subclinical lymph node metastasis in papillary thyroid microcarcinoma:a study of 551 resections. Surgery, 2010, 148(3):526-531.
31.	Vasileiadis I, Karakostas E, Charitoudis G, et al. Papillary thyroid microcarcinoma:clinicopathological characteristics and implications for treatment in 276 patients. Eur J Clin Invest, 2012, 42(6):657-664.
32.	Zhang L, Wei WJ, Ji QH, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma:a study of 1066 patients. J Clin Endocrinol Metab, 2012, 97(4):1250-1257.
33.	American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2009, 19(11):1167-1214.
34.	Takami H, Ito Y, Okamoto T, et al. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg, 2011, 35(1):111-121.
35.	田文, 罗晋.中国与美国甲状腺结节与分化型甲状腺癌诊治指南比较.中国实用外科杂志, 2013, 33(6):475-479.
36.	Popadich A, Levin O, Lee JC, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery, 2011, 150(6):1048-1057.
37.	Hartl DM, Leboulleux S, Al Ghuzlan A, et al. Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma. Ann Surg, 2012, 255(4):777-783.

1. 徐德全, 代文杰.甲状腺髓样癌的靶向治疗.中国普外基础与临床杂志, 2014, 21(12):1579-1582.
2. World Cancer Report. Version 2014. http://www.iarc.fr/en/publications/books/wcr/wcr-order.php.
3. 陈万青, 张思维, 曾红梅, 等.中国2010年恶性肿瘤发病与死亡.中国肿瘤, 2014, 23(1):1-10.
4. Soares P, Celestino R, Gaspar Da Rocha A, et al. Papillary thyroid microcarcinoma:how to diagnose and manage this epidemic? Int J Surg Pathol, 2014, 22(2):113-119.
5. Cupisti K, Lehwald N, Anlauf M, et al. Encapsulation status of papillary thyroid microcarcinomas is associated with the risk of lymph node metastases and tumor multifocality. Horm Metab Res, 2014, 46(2):138-144.
6. Choi SJ, Kim TY, Lee JC, et al. Is routine central neck dissection necessary for the treatment of papillary thyroid microcarcinoma? Clin Exp Otorhinolaryngol, 2008, 1(1):41-45.
7. Yu XM, Wan Y, Sippel RS, et al. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18445 cases. Ann Surg, 2011, 254(4):653-660.
8. 李建新, 杨雨民, 齐欣, 等.甲状腺微小癌的诊断和治疗.中国普外基础与临床杂志, 2012, 19(7):796-798.
9. Kim BY, Jung CH, Kim JW, et al. Impact of clinicopathologic factors on subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Yonsei Med J, 2012, 53(5):924-930.
10. Rosai J, Livolsi VA, Sobrinho-Simoes M, et al. Renaming papillary microcarcinoma of the thyroid gland:the Porto proposal. Int J Surg Pathol, 2003, 11(4):249-251.
11. Lang BH, Lo CY, Chan WF, et al. Prognostic factors in papillary and follicular thyroid carcinoma:their implications for cancer staging. Ann Surg Oncol, 2007, 14(2):730-738.
12. 王深明, 叶润仪.甲状腺微小癌诊断与外科治疗规范化.中华普外科手术学杂志:电子版, 2013, 7(4):246-249.
13. Zaydfudim V, Feurer ID, Griffin MR, et al. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery, 2008, 144(6):1070-1078.
14. Wang Q, Chu B, Zhu J, et al. Clinical analysis of prophylactic central neck dissection for papillary thyroid carcinoma. Clin Transl Oncol, 2014, 16(1):44-48.
15. Costa S, Giugliano G, Santoro L, et al. Role of prophylactic central neck dissection in cN0 papillary thyroid cancer. Acta Otorhinolaryngol Ital, 2009, 29(2):61-69.
16. White ML, Gauger PG, Doherty GM. Central lymph node dissection in differentiated thyroid cancer. World J Surg, 2007, 31(5):895-904.
17. NCCN Guidelines:Thyroid Carcinoma. Version 2, 2013.
18. 代文杰, 徐德全, 殷越.甲状腺结节手术范围合理选择——美国及我国相关指南解读.中国实用外科杂志, 2015, 35(6):604-607.
19. Yoshida A. Guidelines for the management of thyroid tumors. Nihon Geka Gakkai Zasshi, 2012, 113(6):507-511.
20. 鄢丹桂, 张彬.甲状腺乳头状癌临床N0患者颈部淋巴结处理.中华耳鼻喉头颈外科杂志, 2012, 47(3):257-260.
21. Pai SI, Tufano RP. Central compartment neck dissection for thyroid cancer. ORL J Otorhinolaryngol Relat Spec, 2008, 70(5):292-297.
22. 徐德全, 代文杰.分化型甲状腺癌术后促甲状腺激素抑制性治疗进展.中国实用外科杂志, 2013, 33(12):1071-1074.
23. Dănilă R, Andriescu L, Grigorovici A, et al. Differentiated thyroid cancer-staging and prognostic systems. Rev Med Chir Soc Med Nat Iasi, 2005, 109(1):71-76.
24. Shaha AR, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of thyroid. Surgery, 1994, 116(6):1036-1041.
25. 孙荣昊, 李超, 樊晋川.分化型甲状腺癌外科治疗要点问题分析-美国同行见解.中国实用外科杂志, 2014, 34(4):300-302.
26. Niemeier LA, Kuffner Akatsu H, Song C, et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer, 2012, 118(8):2069-2077.
27. Xu D, Lv X, Wang S, et al. Risk factors for predicting central lymph node metastasis in papillary thyroid microcarcinoma. Int J Clin Exp Pathol, 2014, 7(9):6199-6205.
28. Cho SY, Lee TH, Ku YH, et al. Central lymph node metastasis in papillary thyroid microcarcinoma can be stratified according to the number, the size of metastatic foci, and the presence of desmoplasia. Surgery, 2015, 157(1):111-118.
29. Hong YR, Yan CX, Mo GQ, et al. Conventional US, elastography, and contrast enhanced US features of papillary thyroid microcarcinoma predict central compartment lymph node metastases. Sci Rep, 2015, 5:7748.
30. So YK, Son YI, Hong SD, et al. Subclinical lymph node metastasis in papillary thyroid microcarcinoma:a study of 551 resections. Surgery, 2010, 148(3):526-531.
31. Vasileiadis I, Karakostas E, Charitoudis G, et al. Papillary thyroid microcarcinoma:clinicopathological characteristics and implications for treatment in 276 patients. Eur J Clin Invest, 2012, 42(6):657-664.
32. Zhang L, Wei WJ, Ji QH, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma:a study of 1066 patients. J Clin Endocrinol Metab, 2012, 97(4):1250-1257.
33. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2009, 19(11):1167-1214.
34. Takami H, Ito Y, Okamoto T, et al. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg, 2011, 35(1):111-121.
35. 田文, 罗晋.中国与美国甲状腺结节与分化型甲状腺癌诊治指南比较.中国实用外科杂志, 2013, 33(6):475-479.
36. Popadich A, Levin O, Lee JC, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery, 2011, 150(6):1048-1057.
37. Hartl DM, Leboulleux S, Al Ghuzlan A, et al. Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma. Ann Surg, 2012, 255(4):777-783.

Previous Article
Pharmacological Mechanism of Tamoxifen and Its Influence on Ovary Function
Next Article
Research Progress of Preoperative Regional-arterial Chemotherapy in Advanced Gastric Cancer

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research Progress of Lymph Node Dissection in Treatment of cN0 Papillary Thyroid Microcarcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content